Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 1.0-99.0,  Malaria FOR 1,2,3: All of the following must be fulfilled for a volunteer to participate in this trial: 1. Meets age requirements for Arm currently being enrolled. 2. Available for the duration of the trial. 3. Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages. 4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. 5. In good general health and without clinically significant medical history in the opinion of the investigator. 6. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to Study Day 0 and until 1 month after the last vaccination A reliable method of birth control includes one of the following: 1. Confirmed pharmacologic contraceptives (parenteral) delivery; 2. Intrauterine or implantable device to required pregnancy prevention includes the following: 1. Postmenopausal state: defined as no menses for 12 months without an alternative medical cause 2. Surgical sterilization 3. Unmarried AND not sexually active AND menstruating OR not menstruating females 12-17 years of age 4. NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become >=18 years of age, married, or sexually active), the female will be required to start reliable contraception 7. Willing to have blood samples stored for future research. FOR GROUP 4: All of the following must be fulfilled for a volunteer to participate in this trial: 1. Meets age requirements for Arm currently being enrolled. 2. Available for the duration of the trial. 3. Family compound known resident or long-term resident (more than 1 year) of Doneguebougou, Mali or surrounding villages. 4. Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process. 5. In good general health and without clinically significant medical history in the opinion of the investigator. 6. Willing to have blood samples stored for future research. for Groups 1, 2, 3, (Year 2) All of the following must be fulfilled for a volunteer to continue to participate in this trial: 1. Previously enrolled in the study and has received at least 1 vaccination. 2. Available for the duration of the trial. 3. In good general health and without clinically significant medical history in the opinion of the investigator. 4. Females of childbearing potential must be willing to use reliable contraception from 21 days prior to scheduled vaccine dose #4 and until 1 month after the 4th vaccination. -A reliable method of birth control includes one of the following: 1. Confirmed pharmacologic contraceptives (parenteral) delivery; 2. Intrauterine or implantable device to required pregnancy prevention includes the following: 1. Postmenopausal state: defined as no menses for 12 months without an alternative medical cause 2. Surgical sterilization 3. Unmarried AND not sexually active AND menstruatingOR not menstruating females 12-17 years of age 4. NOTE: if a female of childbearing potential s status changes during the course of vaccination through 1 month post vaccination (e.g. they become greater than or equal to 18 years of age, married, or sexually active), the female will be required to start reliable contraception 5. Willing to have blood samples stored for future research. for Group 4 (Year 2): All of the following must be fulfilled for a volunteer to continue to participate in this trial: 1. Previously enrolled in the study 2. Available for the duration of the trial. 3. In good general health and without clinically significant medical history in the opinion of the investigator. 4. Willing to have blood samples stored for future research  FOR 1, 2, 3: An individual will be excluded from participating in this trial if any one of the following is fulfilled: 1. Pregnant, as determined by a positive urine or serum beta human choriogonadotropin (beta-hCG) test (if female). NOTE: Pregnancy is also a criterion for discontinuation of any further vaccine dosing 2. Menstruating females 11 years of age and younger. (In order to avoid cultural implications of further assessing pregnancy potential i.e. sexual activity in this age group.) 3. Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the subject to understand and comply with the study protocol at a level appropriate for the subject s age. 4. Hemoglobin, white blood cell (WBC), absolute neutrophil count, or platelet levels outside the local laboratory defined limits of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and <= Grade 2.) 5. Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory defined upper limit of normal. (Subjects may be included at the investigator s discretion for not clinically significant values outside of normal range and <= Grade 2.) 6. Infected with HIV 7. Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis. 8. Clinically significant prolonged QTc (>450 milliseconds) on screening EKG 9. History of receiving any investigational product within the past 30 days. 10. Current or planned participation in an investigational vaccine study until the last required protocol visit. 11. Medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months. 12. History of a severe allergic reaction or anaphylaxis. 13. Known Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years Autoimmune or antibody-mediated disease including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sj(SqrRoot)(Delta)gren s syndrome, or autoimmune thrombocytopenia Immunodeficiency syndrome Seizure disorder (exception: history of simple febrile seizures) Asplenia or functional asplenia Use of chronic (>=14 days) oral or intravenous (IV) corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0 Allergy to latex or neomycin Adverse reaction to hepatitis A and/or typhoid and/or meningococcal vaccine in the past Adverse reaction to artemether/lumefantrine in the past 14. Receipt of: -Live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks to enrollment